These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 19096980

  • 1. Secondary C-kit mutation is a cause of acquired resistance to imatinib in gastrointestinal stromal tumor.
    Zheng S, Pan YL, Tao DY, Wang JL, Huang KE.
    Scand J Gastroenterol; 2009; 44(6):760-3. PubMed ID: 19096980
    [Abstract] [Full Text] [Related]

  • 2. Pathologic and molecular heterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromal tumors.
    Agaram NP, Besmer P, Wong GC, Guo T, Socci ND, Maki RG, DeSantis D, Brennan MF, Singer S, DeMatteo RP, Antonescu CR.
    Clin Cancer Res; 2007 Jan 01; 13(1):170-81. PubMed ID: 17200352
    [Abstract] [Full Text] [Related]

  • 3. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors.
    Chen LL, Trent JC, Wu EF, Fuller GN, Ramdas L, Zhang W, Raymond AK, Prieto VG, Oyedeji CO, Hunt KK, Pollock RE, Feig BW, Hayes KJ, Choi H, Macapinlac HA, Hittelman W, Velasco MA, Patel S, Burgess MA, Benjamin RS, Frazier ML.
    Cancer Res; 2004 Sep 01; 64(17):5913-9. PubMed ID: 15342366
    [Abstract] [Full Text] [Related]

  • 4. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.
    Wardelmann E, Merkelbach-Bruse S, Pauls K, Thomas N, Schildhaus HU, Heinicke T, Speidel N, Pietsch T, Buettner R, Pink D, Reichardt P, Hohenberger P.
    Clin Cancer Res; 2006 Mar 15; 12(6):1743-9. PubMed ID: 16551858
    [Abstract] [Full Text] [Related]

  • 5. [Small-molecule inhibitors against KIT and PDGFRs especially in GISTs].
    Shiba K, Matsumoto T, Hirota S.
    Gan To Kagaku Ryoho; 2009 Jul 15; 36(7):1080-5. PubMed ID: 19620796
    [Abstract] [Full Text] [Related]

  • 6. Surgical management after neoadjuvant imatinib therapy in gastrointestinal stromal tumours (GISTs) with respect to imatinib resistance caused by secondary KIT mutations.
    Haller F, Detken S, Schulten HJ, Happel N, Gunawan B, Kuhlgatz J, Füzesi L.
    Ann Surg Oncol; 2007 Feb 15; 14(2):526-32. PubMed ID: 17139461
    [Abstract] [Full Text] [Related]

  • 7. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor.
    Bauer S, Yu LK, Demetri GD, Fletcher JA.
    Cancer Res; 2006 Sep 15; 66(18):9153-61. PubMed ID: 16982758
    [Abstract] [Full Text] [Related]

  • 8. KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.
    Bauer S, Duensing A, Demetri GD, Fletcher JA.
    Oncogene; 2007 Nov 29; 26(54):7560-8. PubMed ID: 17546049
    [Abstract] [Full Text] [Related]

  • 9. Pathology of gastrointestinal stromal tumors.
    Hirota S, Isozaki K.
    Pathol Int; 2006 Jan 29; 56(1):1-9. PubMed ID: 16398673
    [Abstract] [Full Text] [Related]

  • 10. Acquired resistance to imatinib and secondary KIT exon 13 mutation in gastrointestinal stromal tumour.
    Bertucci F, Goncalves A, Monges G, Madroszyk A, Guiramand J, Moutardier V, Noguchi T, Dubreuil P, Sobol H.
    Oncol Rep; 2006 Jul 29; 16(1):97-101. PubMed ID: 16786129
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense.
    Negri T, Pavan GM, Virdis E, Greco A, Fermeglia M, Sandri M, Pricl S, Pierotti MA, Pilotti S, Tamborini E.
    J Natl Cancer Inst; 2009 Feb 04; 101(3):194-204. PubMed ID: 19176456
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor].
    Wang CM, Shi YQ, Fu H, Zhao GF, Zhou Y, Du CY, Ye YW.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2010 May 04; 13(5):371-4. PubMed ID: 20499309
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.
    Lasota J, Miettinen M.
    Histopathology; 2008 Sep 04; 53(3):245-66. PubMed ID: 18312355
    [Abstract] [Full Text] [Related]

  • 20. KIT/Val654 Ala receptor detected in one imatinib-resistant GIST patient.
    Tamborini E, Gabanti E, Lagonigro MS, Negri T, Pilotti S, Pierotti MA, Pricl S.
    Cancer Res; 2005 Feb 01; 65(3):1115; author reply 1115. PubMed ID: 15705916
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.